Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Moderate Buy consensus from five analysts (four buys, one sell) with an average 12‑month price objective of $28.67.
• Analyst views are mixed: Weiss Ratings and Wall Street Zen have recent sell calls, while Morgan Stanley and Wells Fargo each set a $33 price target and Wells Fargo rates the stock overweight.
• Shares trade around $8.95 with a market cap of $540.94 million; the company reported ($0.80) EPS last quarter (matching estimates), is expected to post about -3.29 EPS for the year, and has strong liquidity (quick/current ratios 7.75) with institutional ownership of 18.08%.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $28.6667.

A number of brokerages recently commented on KYTX. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Wall Street Zen cut shares of Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Finally, Wells Fargo & Company boosted their price objective on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an "overweight" rating in a research report on Tuesday, December 16th.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of hedge funds have recently modified their holdings of KYTX. Bank of America Corp DE increased its position in shares of Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock valued at $81,000 after acquiring an additional 6,400 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Kyverna Therapeutics by 31.1% in the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company's stock valued at $132,000 after acquiring an additional 16,267 shares during the period. AQR Capital Management LLC purchased a new position in shares of Kyverna Therapeutics in the first quarter valued at about $137,000. Rhumbline Advisers increased its position in shares of Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock valued at $61,000 after acquiring an additional 5,694 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Kyverna Therapeutics in the second quarter valued at about $107,000. Hedge funds and other institutional investors own 18.08% of the company's stock.

Kyverna Therapeutics Price Performance

Shares of NASDAQ:KYTX opened at $8.95 on Friday. The stock has a market cap of $540.94 million, a PE ratio of -2.45 and a beta of 2.62. The company's fifty day moving average is $8.26 and its 200 day moving average is $7.88. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $13.67. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.11.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its earnings results on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, hitting analysts' consensus estimates of ($0.80). Research analysts anticipate that Kyverna Therapeutics will post -3.29 earnings per share for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.